XVIII International AIDS Conference Novel HIV-1 Protease Inhibitors Containing bis-Tetrahydrofuran or a Novel Polycyclic Ligand, Pyranofuran 1 Depts of.

Slides:

Advertisements

Similar presentations

Use of Bioisosteric Replacement Tools to Obtain Mutation- Resistant Antivirals Mattia CF Prosperi University of Roma TRE Faculty of Computer Science Engineering.

Advertisements

Immune Activation/Inflammation and HIV Disease Prof. Georg Behrens Department for Clinical Immunology and Rheumatology Hannover Medical School Germany.

Observation of New Strong High-Frequency Feature in Two-Photon Absorption Spectrum of GFP and its Description within Three-Level Model with Resonance Enhancement.

Office of Infectious Diseases Computational Challenges for Infectious Diseases Michael Shaw, PhD OID/Office of the Director.

Antiviral Immunity and Transmission June 19, 2011 Abst. #: TUAA0105 Maraviroc-resistant subtype B primary HIV-1 induced in vitro selection became highly.

AIDS2012 TUAA0301 Pre-clinical Evaluation of HIV Replication Inhibitors that Target the HIV Integrase- LEDGF/p75 Interaction Frauke Christ, Chris Pickford,

Fluorescent proteins Green Fluorescence Protein (GFP) from jellyfish : Revolutionized medical and biological science by providing a way to monitor how.

Fig 1: HIV-1/HCV and HIV-1/HBV Co-Infection/Co- Culture Systems Philippe A. Gallay 1, Udayan Chatterji 1, Michael Bobardt 1, Daren Ure 2, Dan Trepanier.

The use of fluorescence resonance energy transfer (FRET) to study the interaction between CD147 and MCT1 The principle of FRET MCT1 CD147 s s s s N- terminus.

Development of High-throughput Screening Assay for Small Molecule Inhibitor(s) of PIAS1 Bourns College of Engineering Department of Bioengineering Vicente.

HIV and AIDS Human Immunodeficiency Virus (HIV) is the virus that causes Acquired Immunodeficiency Syndrome (AIDS).

1111 Discovery Novel Allosteric Fragment Inhibitors of HIV-1 Reverse Transcriptase for HIV Prevention A/Prof Gilda Tachedjian Retroviral Biology and Antivirals.

HIV-1 Protease HIV-1 Protease is one of the targets in the therapeutic treatment of AIDS. It cleaves the nascent polyproteins of HIV-1 and plays an essential.

Dissociation of an antiviral compound from the internal pocket of human rhinovirus 14 capsid (Y. Li, Z. Zhou, and C. B. Post) Richard S. L. Stein CS 379a.

HIV GP120 Envelope Protein

The Unique Resistance Profile of Tipranavir Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.

Combination of Drugs and Drug-Resistant Reverse Transcriptase Results in a Multiplicative Increase of Human Immunodeficiency Virus Type 1 Mutant Frequencies.

Fluorescent proteins Green Fluorescence Protein (GFP) from jellyfish : Revolutionized medical and biological science by providng a way to monitor how individual.

Antivirals for HIV Yasir Waheed, PhD. Some HIV Facts HIV – the Human Immunodeficiency Virus is the retrovirus that causes AIDS HIV belongs to the retrovirus.

FRET(Fluorescent Resonance Energy Transfer)

Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-

Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.

Lycorine, its use to inhibit flavivirus activity through the suppression of viral RNA synthesis. An Anti-Flavivirus Therapeutic Available for license Presented.

AIDS, Vienna 2010 MOAA01 Novel therapeutic strategies The LEDGINs: rational design of first in class LEDGF/p75-integrase inhibitors with potent antiviral.

CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist Andre J Marozsan Progenics Pharmaceuticals, Inc.

HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.

Natural polymorphisms in the protease of HIV-1 isolates explain hypersusceptibility to protease inhibitors A.F. Santos, D.M. Tebit, M.S. Lalonde, A. Ratcliff,

KEY CONCEPT Some viral diseases can be prevented with vaccines.

Lab of Immunoregulation Berkower Lab Weiss Lab -- Angelo Spadaccini -- Russell Vassell -- Yisheng Ni -- Yong He -- Yisheng Ni -- Yong He –Hong Chen --

Non-Infectious Papilloma virus–like Particles (VLPs) inhibit HIV-1 replication: Implications for immune control of HIV-1 replication by IL-27. Laboratory.

Project 1: Anti-HIV Mechanisms of NK-1R Antagonists PI: Wenzhe Ho Co-PI: Steven D. Douglas.

Quantitative 3D Video Microscopy of HIV Transfer Across T Cell Virological Synapses Anna Buch Wolfgang Hübner et al., Science, 2009.

Samudrala group - overall research areas CASP6 prediction for T Å C α RMSD for all 70 residues CASP6 prediction for T Å C α RMSD for all.

Remodeling of gp-41-C34 Peptide Leads to Highly Effective Inhibitors of the Fusion of HIV-1 with target cells Promising anti-1 peptide developed Nina Pollak.

Personalized Lung Cancer Treatment: Targeting Stem Cell Pathways David M. Jablons, M.D. Professor and Chief Thoracic Surgery Ada Distinguished Professor.

HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.

BIT225 Reduces the Intracellular HIV-1 Burden Within Monocyte Derived Dendritic Cells, Resulting in Reduced Transfer of Virus to more Permissive CD4 +

Table S1. HTS positive hits.. Figure S1. Isogenic bortezomib (Btz) resistant mouse and human cell models. The indicated human (MM.1S and U266) and mouse.

Ensemble Approaches Yield New Scaffolds and New Binding Sites Heather A. Carlson Department of Medicinal Chemistry College of Pharmacy University of Michigan.

1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.

ROLE OF CCR5 LEVELS IN HIV-1 EVOLUTION AND PATHOGENESIS ANJALI JOSHI Assistant Professor Center of Emphasis in Infectious Diseases Department of Biomedical.

Basics of Human Immunodeficiency Virus (HIV) Brian Rybarczyk, PhD University of North Carolina- Chapel Hill.

항바이러스제 Ritonavir 양혜란. Ritonavir 화학명 1,3-Tiazol-5-ylmethyl[3-hydroxy-5-[3-methyl-2-[methyl-[(2-propan-2- yl-1,3-thiazole-4-yl)methyl]carbamoyl]-aminobutanoyl]amino-1,6-

Epigenetic drug Gar1041 in combination with antiretroviral therapy (ART) transiently reduces the proviral DNA reservoir in SIVmac251- infected macaques.

IPC Friedrich-Schiller-Universität Jena 1 Radiationless excitation energy transfer requires interaction between donor and acceptor  Emission spectrum.

Site-Directed Mutagenesis

Date of download: 6/3/2016 From: Report of the NIH Panel To Define Principles of Therapy of HIV Infection* Ann Intern Med. 1998;128(12_Part_2):

Pharmaceutical Approaches to Antiviral Drug Discovery

Nehad A. El Sayed, Amal A. H. Eissa, Reem K. Arafa and Ghada F. El Masry* Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University.

APPLICATIONS OF ANIMAL CELL CULTURE

Live visualization of hemagglutinin dynamics during infection by using biarsenically labeled replication competent Influenza A virus Shashank Tripathi1,2,

A flavone-based inhibitor of in vitro human rhinovirus replication induces resistant mutations in capsid protein VP4. Céline Lacroixa, Hari Babu Bollikollac,

Interferon epsilon promotes HIV restriction at multiple steps of viral replication Albert Garcia-Minambres1,2, Sahar G Eid1,2, Niamh E Mangan3,4, Corinna.

LPV-RTV versus LPV-RTV + ZDV-3TC in Treatment-Naïve MONARK Trial

HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis

Interaction between G Protein-Coupled Receptor 143 and Tyrosinase: Implications for Understanding Ocular Albinism Type 1 Elisabetta De Filippo, Anke.

Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure C. Suñé, L. Brennan, D.R. Stover,

by Fabian Stavenuiter, and Laurent O. Mosnier

A Fluorescence Resonance Energy Transfer Sensor Based on Maltose Binding Protein Xianhui Li

Asymmetric Activation of the Hsp90 Dimer by Its Cochaperone Aha1

Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV

Li Huang Duke University, North Carolina, USA

Research Techniques Made Simple: Methodology and Applications of Förster Resonance Energy Transfer (FRET) Microscopy Joshua A. Broussard, Kathleen J.

Anna Celli, Debra Crumrine, Jason M. Meyer, Theodora M. Mauro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Aim What happens when a bacteria or virus mutates?

Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure C. Suñé, L. Brennan, D.R. Stover,

Asymmetric Activation of the Hsp90 Dimer by Its Cochaperone Aha1

A ROP GTPase Signaling Pathway Controls Cortical Microtubule Ordering and Cell Expansion in Arabidopsis Ying Fu, Tongda Xu, Lei Zhu, Mingzhang Wen, Zhenbiao.

Estimation of [cAMP]i changes using FRET in NCI-H292 cells.

Presentation transcript:

XVIII International AIDS Conference Novel HIV-1 Protease Inhibitors Containing bis-Tetrahydrofuran or a Novel Polycyclic Ligand, Pyranofuran 1 Depts of Hematology and Infectious Diseases, Kumamoto Univ; 2 Kumamoto Health Science Univ; 3 Depts. of Chem & Med Chem, Purdue Univ; 4 Experimental Retrovirology Section, NCI, NIH. Kazuhiko Ide 1, M. Aoki 1,2, Y. Koh 1, M. Amano 1, S. Kulkarni 3, D.D. Anderson 3, B. Chapsal 3, R. Yedidi 4, D. Das 4, A.K. Ghosh 3, and H. Mitsuya 1,4

Background HAART made a major impact on the morbidity of HIV-1-infected individuals and significantly extended their survival. The emergence of multi-drug-resistant viruses (HIV-1 MDR ) is still one of the major concerns. Continuous efforts are required to develop more potent and safer therapeutics with high genetic barrier.

Darunavir DRV possesses a dual antiviral activity, i.e., protease inhibition and protease dimerization inhibition. Koh & Mitsuya. J Biol Chem. 282: , 2007 The presence of bis-THF is important for the antiviral activity of DRV. bis-THF bis-tetrahydrofuran Koh, Ghosh & Mitsuya. Antimicrob Agents Chemother 47: , 2003

GRL-0878 GRL-0888 Major Isomer Minor Isomer bis-THF ( Cis ) ( Trans ) GRL-1388GRL-1398 polycyclic ligand (pyranofuran)

DrugEC 50 (nM)CC 50 (μM)* Selectivity Index SQV ,100 APV19.6>100>5,100 ATV ,400 DRV3.3>100>30, , , >100>27, ,800 *Selectivity index = CC 50 / EC 50 Four New Compounds Are Comparably or More Potent against HIV Compared to DRV

Virus EC 50 (nM) ATVAPVDRV HIV-1 WT (X4)1.9 (1)35.1 (1)3.5 (1)6.0 (1)6.8 (1)3.2 (1)0.3 (1) HIV-1 MDR/B (X4)228 (120)328.8 (9)19.4 (6)59.1 (10)82.3 (12)4.7 (2)4.8 (16) HIV-1 MDR/C (X4)25.4 (13)265.2 (8)5.2 (1)34.5 (6)58.5 (9)4.0 (1)1.1 (4) HIV-1 MDR/MM (R5)68.9 (36)402.2 (11)21.4 (6)301.0 (50)312.8 (46)21.3 (7)2.6 (9) HIV-1 MDR/EV (R5)39.0 (21)>1,000 (28)214.6 (61)>1,000 (167)>1,000 (147)530.3 (166)23.5 (78) (fold change), blue ： 5-10 times, red ： >10 times GRL-1398 Is More Potent against a Wide Spectrum of HIV MDR Isolates than DRV

Virus EC 50 (nM) DRV GRL-1388 GRL-1398 HIV-1 WT 3.3 (1)3.2 (1)0.3 (1) HIV-1 DRV R P (9)24.6 (8)3.3 (11) HIV-1 DRV R P (65)151 (47)21.9 (73) GRL-1398 Is Active against DRV-resistant HIV Variants (Fold-change)

CFP Monomer-monomer Interactions Protease or Polyprotein Dimerization FRET YFP RT Yellow Fluorescent Protein PR F/P Cyan Fluorescent Protein PR AAAAA Spacer pHIV-1 NL43sma 238 AA RT 99 AA Apa FRET-HIV-1 Expression System Protease or polyprotein Monomer Intermolecular FRET (Fluorescence Resonance Energy Transfer)-based If CFP A/B ratios are < 1.0, there is no FRET or dimerization Protease or polyprotein Monomer nm

CFP A/B ratio NoneGRL-1398GRL-1388DRV (μM) GRL-1388 and have PDI activity Dimerization － Dimerization ＋ p = 0.07 p < p = 0.15 p = p =

Cells used : MT4 A28S/M46I Confer Resistance to GRL-1398 on HIV NL4-3 GRL-1388 GRL-1398 DRV L10F A28S M46I L10F A28S M46I V82I L10F V32I M46L APV L10F V32I L33F M46L I54M A71V Weeks

GRL-1398 Resists against Emergence of HIV DRV R with a Mixture of 8 HIV-1 MDR Isolates GRL-1388 GRL-1398 DRV Cells used : MT4 Weeks L10I L33I M36I M46I L63P A71V V82A L90M

VAL82 VAL32 ILE84 ASP30 ASP29 ALA28 ASP29’ ASP30’ GLY49 GLY48 ILE47 ASP25 PRO81’ VAL82’ ILE84’ ILE50’ H2OH2O GLY27’ ALA28’ GRL-1398 Has Tight Interactions with PR

Summary GRL-1388 and -1398, containing a novel structure-based designed ligand, were comparably or more potent compared to DRV. Although GRL-1398 had moderate PDI activity as compared to DRV, GRL-1398 exhibited more potent anti-HIV activity against DRV- resistant HIV variants.

Conclusions GRL-1398 has activity against protease’s enzymatic activity and dimerization activity with high genetic barrier. It is warranted that the compounds, especially GRL-1398, be further studied as potential therapeutics for HIV wt and HIV-1 MDR infection.

Thank you for your attention